This website is not for investment purposes. Contact the company for investing documents.

Copyright © 2019 SageMedic Corporation. All rights reserved.

Fig. 1 shows 3D tumors that have been treated with various concentrations of cisplatin.

The Next Generation of Precision Medicine

Several studies have shown that 8 out of 10 cancer patients do not benefit from genomic testing.  
These patients just don’t have mutations for which there is a targeted drug and this is not going to change anytime soon.  SageMedic’s next-generation precision medicine assay is a genome-free high throughput ex-vivo test that can match the cancer from almost all patients to the right therapy that is going to work best for them.  By reducing the guesswork, SageMedic has the potential to dramatically improve the safety, efficacy, and cost-effectiveness of cancer therapy.  In other words, with SageMedic’s test, patients will have a much higher chance of a tumor response, better quality of life, and increase survival, while health care providers, cancer centers, and payors will benefit from improved efficiency of care.

 

SageMedic Identifies an Individual’s Optimal Therapy with Live Tumor Tissue
SageMedic’s proprietary technology uses a biopsy of the patient’s own live cancer tissue to create hundreds of biologically similar 3D micro-tumors in our lab.  SageMedic’s 3D micro-tumors are then exposed to multiple treatment options, the responses are measured, and within a week the results will be sent to the physician. 

Shown below are 3D tumors that have been treated with a placebo and Cisplatin.